FibroGen (NASDAQ:FGEN) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a report issued on Friday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of FibroGen in a research report on Thursday, February 20th.

FibroGen Stock Performance

Shares of NASDAQ:FGEN opened at $0.44 on Friday. FibroGen has a fifty-two week low of $0.18 and a fifty-two week high of $2.80. The business has a 50-day simple moving average of $0.51 and a two-hundred day simple moving average of $0.43. The firm has a market cap of $44.27 million, a price-to-earnings ratio of -0.36 and a beta of 0.82.

Hedge Funds Weigh In On FibroGen

Hedge funds have recently bought and sold shares of the business. Two Sigma Securities LLC purchased a new stake in shares of FibroGen during the 4th quarter valued at about $27,000. Velan Capital Investment Management LP purchased a new stake in shares of FibroGen during the 4th quarter valued at about $42,000. XTX Topco Ltd increased its position in shares of FibroGen by 423.8% during the 4th quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 77,693 shares during the last quarter. Franklin Street Advisors Inc. NC increased its position in shares of FibroGen by 100.0% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 100,000 shares during the last quarter. Finally, FMR LLC increased its holdings in FibroGen by 21.8% in the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 68,569 shares in the last quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.